MabSelect™ family overveiw:

• MabSelect: high throughput capture of MAbs
• MabSelect SuRe™: harsh, rigorous and cost-effective CIP and sanitization protocols with industry standard reagents, i.e. 0.1-0.5 M NaOH
• MabSelect Xtra™: capture of high titer feedstreams requiring higher capacity

内容摘要：
apture the lead in MAb development - The MabSelect family

Commercial success of approved biopharmaceuticals  and growing numbers of protein-based drug candidates have led to projections of metric tons of monoclonal  antibodies (MAbs) being required in a few short years. To meet this demand cell culture capacity is i with reactors in the 12-15 000 L range and larger coming on-line. Expression levels, currently in the 0.1-1.0 g/L range, are expected to increase several-fold. In downstream processing, efforts are directed at improving process economy by decreasing the number and cost of unit operations. Current trends in antibody production indicate an increased use of protein A chromatography media for product capture.
Protein A-based media: the benefits
• High selectivity enables a reduction in the number and size of subsequent unit operations through high purity and yield results
• Insensitivity to variations in additives, pH and conductivity facilitates the use of generic protocols
• Already used for purification of almost all licensed MAb products
• Commonly validated for both viral clearance and subsequent inactivation

Evolving demands on media
Chromatography media for clinical- to full-scale MAb production must handle large volumes of higher titer feedstreams, have the chemical and physical stability to withstand rigorous cleaning-in-place (CIP) procedures while maintaining dynamic binding capacity, and help
reduce the overall cost of manufacturing. Our family of MabSelect™ rProtein A chromatography media meet these demands. ……